Journal
CURRENT DRUG TARGETS
Volume 9, Issue 3, Pages 204-209Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945008783755584
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL-34343, HL-30568, R01 HL089328, P01 HL034343] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089328, P01HL030568, P01HL034343] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The mouse has proven to be an excellent model for testing apolipoprotein mimetic peptides as agents to treat a variety of vascular inflammatory conditions including atherosclerosis, cognitive dysfunction associated with arteriole inflammation, chronic rejection of transplanted hearts, and scleroderma. The mechanism of action appears to relate to the ability of these peptides to preferentially bind pro-inflammatory oxidized lipids and is independent of the chirality of the peptides since peptides synthesized from either D- or L-amino acids appear to be equally effective.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available